scholarly journals ESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in laryngeal squamous cell carcinoma

2019 ◽  
Vol 33 (6) ◽  
Author(s):  
Zhisen Shen ◽  
Yan Hu ◽  
Chongchang Zhou ◽  
Jie Yuan ◽  
Jie Xu ◽  
...  
2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Zhisen Shen ◽  
Chongchang Zhou ◽  
Jinyun Li ◽  
Dong Ye ◽  
Hongxia Deng ◽  
...  

The purpose of this study was to evaluate the contribution ofSHISA3promoter methylation to laryngeal squamous cell carcinoma (LSCC).SHISA3promoter methylation status and expression were determined using methylation-specific polymerase chain reaction (MSP) and quantitative real-time PCR (qRT-PCR) in 93 paired LSCC and adjacent normal tissues, respectively. Furthermore, the regulatory function of theSHISA3promoter fragment was analyzed using a luciferase reporter assay. The results reveal that there is a significant increase inSHISA3methylation in LSCC tissues compared with corresponding nontumor tissuesP=4.58E-12. The qRT-PCR results show a significant association betweenSHISA3methylation and expression in LSCCP=1.67E-03. In addition, the area under the receiver operating characteristic curve was 0.91. Consequently, a log-rank test and multivariate Cox analysis suggest thatSHISA3promoter hypermethylation is a predictor of poor overall survival for LSCC (log-rankP= 0.024; HR = 2.71; 95% CI = 1.024–7.177;P= 0.047). The results indicate thatSHISA3promoter hypermethylation might increase the risk of LSCC through regulation of gene expression and is a potential diagnostic and prognostic biomarker for LSCC.


2020 ◽  
Vol 48 (4) ◽  
pp. 030006052091925
Author(s):  
Jun Ge ◽  
Li Jiang ◽  
Yuke Tian ◽  
Min Zheng ◽  
Meiling Huang ◽  
...  

Objectives This study aimed to explore the expression profile of the Forkhead box protein L2 gene ( FOXL2) and to determine its prognostic value and associated epigenetic and genetic alterations in patients with laryngeal squamous cell carcinoma (LSCC). Materials and methods Data for a subset of patients with LSCC (N = 116) were extracted from the head and neck squamous cell carcinoma dataset of The Cancer Genome Atlas and analyzed in relation to FOXL2 expression and survival. Results Aberrant FOXL2 expression was an independent prognostic factor for progression-free survival (PFS) (hazard ratio (HR): 2.63, 95% confidence interval (CI): 1.34–5.18) and overall survival (OS) (HR: 2.39, 95%CI: 1.28–4.46). Two gene-body CpG sites (cg10554436 and cg23637494) were moderately and positively correlated with FOXL2 expression. DNA amplification (+2/+1) was common (82/115, 71%) in LSCC, and FOXL2 expression was significantly upregulated in the high-amplification group (+2) compared with copy-neutral (0) cases. Conclusion Aberrant FOXL2 expression may be a novel prognostic biomarker for PFS and OS among patients with LSCC. FOXL2 upregulation may be related to gene-body hypermethylation and DNA amplification.


2014 ◽  
Vol 134 (7) ◽  
pp. 753-759 ◽  
Author(s):  
Yong Shi ◽  
Hong-Li Gong ◽  
Liang Zhou ◽  
Jie Tian ◽  
Yang Wang

Head & Neck ◽  
2013 ◽  
Vol 36 (8) ◽  
pp. 1103-1108 ◽  
Author(s):  
Stefano Pierini ◽  
Stanislav H. Jordanov ◽  
Atanaska V. Mitkova ◽  
Ivan J. Chalakov ◽  
Mincho B. Melnicharov ◽  
...  

2017 ◽  
Vol 23 ◽  
pp. 3635-3640 ◽  
Author(s):  
Zhisen Shen ◽  
Bing Cao ◽  
Lexi Lin ◽  
Chongchang Zhou ◽  
Dong Ye ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document